Image Place holder

Joseph Markowitz, MD, PhD


Specialty: Medical Oncology
Program: Cutaneous Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Markowitz is interested in cutaneous oncology and melanoma in particular. He will engage in clinical translational research efforts in tumor immunology and immunotherapy.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • The Ohio State University - Medical Oncology
  • The Ohio State University -
  • The Ohio State University - Advanced Medical Oncology

Residency:

  • The Ohio State University - Internal Medicine

Medical School:

  • University of Maryland Baltimore - MD, PhD
Participating Trials

CLINICAL TRIAL 17974
An Open-Label, Multicenter, Dose-Escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; RTA 408; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17937
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable; Urelumab
Open

CLINICAL TRIAL 18309
A Phase 2, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; Proleukin (Interleukin-2); TIL
Open

CLINICAL TRIAL 18686
An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa (Intron® A, HDI) versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients with Surgically Resected Melanoma
Condition: Cutaneous
Intervention: PEG-Intron (Peginterferon Alfa 2B); interferon alfa
Open

CLINICAL TRIAL 18569
A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Condition: Cutaneous
Intervention: Alkeran (Melphalan); DTIC (Dacarbazine); Dacarbazine; Ipilimumab; Melphalan; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18916
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance
Condition: Cutaneous
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 18874
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); HBI-8000 (chidamide); Nivolumab
Open

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18989
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: PV-10; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18377
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2; Nivolumab; Proleukin (Interleukin-2); TIL
Open

CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Cutaneous
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18975
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Condition: Cutaneous
Intervention: REGN2810
Open

CLINICAL TRIAL 18597
Phase I Study of Escalating Doses of XL888 with Vemurafenib plus Cobimetinib for Patients with Unresectable BRAF Mutated Stage III/IV Melanoma
Condition: Cutaneous
Intervention: Cobimetinib; RO5185426 (Vemurafenib); Vemurafenib (Zelboraf); XL888
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson Iii WE. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immun. 2017 Jul. Pubmedid: 28688082.
  • Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE. Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights. 2017 Feb;11. Pubmedid: 28469417. Pmcid: PMC5345922.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE. Structural characterization of NRAS isoform 5. Protein Sci. 2016 May;25(5):1069-1074. Pubmedid: 26947772. Pmcid: PMC4838646.
  • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
  • Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Nole TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016 Dec;7(49):81172-81186. Pubmedid: 27783987. Pmcid: PMC5348384.
  • Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE, Basu S, Bai XF. A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. J Immunol. 2016 Aug;197(4):1489-1497. Pubmedid: 27385779. Pmcid: PMC4975953.
  • Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE. MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther. 2016;9:5931-5941. Pubmedid: 27729802. Pmcid: PMC5047719.
  • Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WE. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immun. 2015 Feb;64(2):149-159. Pubmedid: 25305035. Pmcid: PMC4504424.
  • Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, Walker CJ, Markowitz J, Carson WE, Eisfeld AK, de la Chapelle A. MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A. 2015 Dec;112(49):E6744-E6751. Pubmedid: 26582795. Pmcid: PMC4679059.
  • Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A. 2014 Mar;111(11):4179-4184. Pubmedid: 24586049. Pmcid: PMC3964043.
  • Dhar A, Mallick S, Ghosh P, Maiti A, Ahmed I, Bhattacharya S, Mandal T, Manna A, Roy K, Singh S, Nayak DK, Wilder PT, Markowitz J, Weber D, Ghosh MK, Chattopadhyay S, Guha R, Konar A, Bandyopadhyay S, Roy S. Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide. Biopolymers. 2014 Jul;102(4):344-358. Pubmedid: 24839139. Pmcid: PMC4107132.
  • Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother. 2014 Jan;37(1):55-62. Pubmedid: 24316557. Pmcid: PMC4174542.
  • Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal. 2014 Apr;7(321):ra36. Pubmedid: 24736457. Pmcid: PMC4165404.
  • Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013 Jul;140(1):13-21. Pubmedid: 23828498. Pmcid: PMC3773691.
  • Markowitz J, Carson WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta. 2013 Jan;1835(1):100-109. Pubmedid: 23123827. Pmcid: PMC3670606.
  • Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1:10. Pubmedid: 24829747. Pmcid: PMC4019895.
  • Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep;15(18):5895-5901. Pubmedid: 19737952. Pmcid: PMC2774354.
  • Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont). 2008 Oct;5(10):29-36. Pubmedid: 19724721. Pmcid: PMC2695757.
  • Markowitz J, MacKerell AD, Weber DJ. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem. 2007 Jun;7(6):609-616. Pubmedid: 17584159.
  • Wright NT, Varney KM, Ellis KC, Markowitz J, Gitti RK, Zimmer DB, Weber DJ. The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy. J Mol Biol. 2005 Oct;353(2):410-426. Pubmedid: 16169012.
  • Markowitz J, Rustandi RR, Varney KM, Wilder PT, Udan R, Wu SL, Horrocks WD, Weber DJ. Calcium-binding properties of wild-type and EF-hand mutants of S100B in the presence and absence of a peptide derived from the C-terminal negative regulatory domain of p53. Biochemistry-Us. 2005 May;44(19):7305-7314. Pubmedid: 15882069.
  • Markowitz J, Mackerell AD, Carrier F, Charpentier TH, Weber DJ. Design of Inhibitors for S100B. Curr Top Med Chem. 2005;5(12):1093-1108. Pubmedid: 16248785.
  • Markowitz J, Chen I, Gitti R, Baldisseri DM, Pan Y, Udan R, Carrier F, MacKerell AD, Weber DJ. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem. 2004 Oct;47(21):5085-5093. Pubmedid: 15456252.
  • Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004 Aug;279(32):34071-34077. Pubmedid: 15178678.
  • Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 2002 Oct;530(1-3):53-58. Pubmedid: 12387865.